R&D Trends

CrownBio launches grant program to Fund Preclinical Oncology Research

Monday, November 20, 2017

Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced the launch of a grant program supporting oncology research scientists which provides funding for projects that show promise for scientific advancement of Patient Derived Xenograft (PDX) technology.

[Read More]

Purdue Pharma invests in oncology R&D

Wednesday, November 15, 2017

Purdue Pharma announced completion of significant oncology related investments as part of its ongoing efforts to diversify its scientific research into areas of high unmet medical need. Through these investments, executed over a multi-year period and capped recently in 2017, Purdue is establishing a portfolio of drug candidates with the potential to deliver new cancer therapies to patients within the next five years.

[Read More]

Myriad collaborates with Department of Veterans Affairs

Tuesday, November 14, 2017

Assurex Health, a wholly-owned subsidiary of Myriad Genetics, announced that the Department of Veterans Affairs (VA) recently initiated a national, multicenter trial to evaluate the company’s GeneSight test to help improve health outcomes for veterans diagnosed with major depressive disorder (MDD). Approximately 20% of the 2.6 million veterans who deployed to Iraq or Afghanistan returned with MDD or a related mental health condition, and tragically suicide rates for veterans are twice that of the U.S. population.

[Read More]

NPL, Imperial College London launch virtual lab

Friday, November 10, 2017

NPL, the UK’s National Measurement Institute (NMI), and SynbiCITE at Imperial College London, have announced the establishment of a new £7 million virtual lab to underpin their joint Centre for Engineering Biology, Metrology and Standards to help the UK synthetic biology industry improve the manufacturing and adoption of new products – in partnership with LGC and NIBSC.

[Read More]

The Pistoia Alliance AbVance Project hits a key milestone

Friday, November 10, 2017

The Pistoia Alliance, a global, not for profit alliance that works to lower barriers to innovation in life sciences R&D, has announced that its project to increase knowledge of antibody (Ab) structures has reached its first major milestone—12 antibody structures have been deposited into the European Bioinformatics Institute’s (EMBL-EBI) Protein Data Bank (PDB). The goals of the project are to generate novel Ab structures and improve Ab structural data sharing across the life sciences. This will increase researchers’ predictive power and their ability to accurately model Ab structures; considerably reducing the time and cost associated with generating experimental data to support decision-making in drug projects.

[Read More]

Merck, CDRD partner on Canadian life sciences ecosystem

Monday, November 6, 2017

The Canadian scientific community gathered in Ottawa this week to engage in a national dialogue on science, technology and innovation policy at the annual Canadian Science Policy Conference. Just prior to the Keynote Address at this event by the Honorable Kirsty Duncan, Minister of Science, Merck Canada and CDRD (The Centre for Drug Research and Development) announced the establishment of a new $1.5M Merck-CDRD Innovation Fund. This fund will go directly towards the advancement of projects of high therapeutic potential carried out at CDRD in collaboration with academic researchers.

[Read More]

Michael J. Fox Foundation, 23andMe collaborate

Tuesday, October 31, 2017

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and 23andMe announced a collaboration to build a large, diverse cohort of both patients and control volunteers who have consented to participate in research. This cohort will provide researchers, drug makers, regulators and payers critical insight into the lived experience, genetics and variability of Parkinson’s disease. The study, Fox Insight (foxinsight.org), is open to anyone 18 or older worldwide with or without Parkinson’s disease and aims to recruit tens or even hundreds of thousands of patients to contribute data.

[Read More]